Dermatica / Rosacea Treatment
PERSONALISED FORMULA · OPTIONAL ORAL DOXYCYCLINE
Ivermectin 1% and metronidazole 0.75% — the two best-evidenced topicals for rosacea, at their approved strengths, with the retinoid correctly left out. The best pool this company builds. The headline above it promises to clear rosacea for good, which is not a thing that can be done.
Worth buying for a specific person with a specific problem. Read who.
ASSESSED ON 75% OF THE MODEL. 2 CRITERIA LEFT UNSCORED — SEE SCORING FOR WHY.
If you are offered the doxycycline, ask for the milligrams before you agree. Forty and a hundred are different drugs in every way that matters here.
The verdict
The pool is the best thing Dermatica builds. Ivermectin at 1% is the concentration of Soolantra and the strongest evidence position in topical rosacea. Metronidazole at 0.75% is the concentration of MetroGel and has been the standard for decades. Azelaic acid reaches 20%, above the 15% approved for rosacea as Finacea. Niacinamide at 4% supports a barrier that rosacea leaves permanently compromised. Three approved drugs at approved strengths, published as numbers on the page you buy from, for $29.95 a month against branded products that cost several times that.
The exclusion matters as much as the inclusions. There is no tretinoin here. Retinoids commonly aggravate rosacea, and a company running a tretinoin-centred catalogue could easily have dropped it into this pool as it did on three other pages. It did not. Combined with the skin glow page, where the hydroquinone and the corticosteroid were also left out, this is now a demonstrable pattern: somebody at Dermatica is choosing pools by indication rather than by inventory.
Then the headline says 'Clear rosacea for good with prescription skincare'. Rosacea is chronic and relapsing. There is no cure, treatment controls it, and stopping brings it back — which the page's own second paragraph concedes when it calls rosacea 'a persistent skin condition', and which its own FAQ concedes again when it explains that triggers cause flares. Of every claim across five Dermatica pages this is the only one that is not an omission or an overreach but a straightforward promise of something that does not exist.
The oral is the other problem, and it is the sharper one. A 16-week doxycycline course is offered at $59.99 with no dose stated. For rosacea the dose is the entire clinical question: sub-antibiotic doxycycline at 40 mg modified-release is the only oral therapy the FDA has approved for the condition, matches 100 mg on lesion counts, and exerts negligible selection pressure for resistance. The 100 mg antimicrobial dose is no more effective, carries the gastrointestinal adverse events almost exclusively, and drives resistance. A company whose distinguishing virtue is printing numbers has left out the one number that decides which drug you are taking.
- Ivermectin 1% — the best-evidenced topical for rosacea, at exactly the approved concentration.
- Metronidazole 0.75% — the established first-line agent, at an approved concentration.
- Azelaic acid reaching 20%, above the 15% approved for rosacea.
- No tretinoin in the pool. Retinoids aggravate rosacea, and this company left its flagship drug out.
- Niacinamide 4% for a barrier that rosacea leaves impaired — the right adjunct at a real dose.
- All topical concentrations published on the page you buy from.
- The oral is scoped as a defined 16-week course rather than an open-ended subscription.
- The trigger-avoidance FAQ is accurate and useful: foods, alcohol, extreme temperatures, stress, and keeping the rest of the routine gentle.
- Eight weeks is an honest timeline for topical rosacea therapy.
- The aetiology paragraph is properly hedged — 'exact causes aren't known yet'.
- $29.95 a month against branded equivalents that cost several times more.
- 'Clear rosacea for good' promises a cure for a chronic relapsing condition that has none.
- The same page calls rosacea 'persistent' two paragraphs later, and its FAQ explains that triggers cause flares.
- 'Around 10% of us have rosacea' is roughly double the pooled global prevalence of about 5%.
- A 16-week oral doxycycline course is sold with no dose stated anywhere.
- No mention of antibiotic resistance, on a page selling four months of an oral antibiotic.
- No photosensitivity warning for doxycycline, in a condition where ultraviolet is a named trigger.
- Ultraviolet is listed among the causes and sunscreen is not mentioned once.
- No pregnancy warning — the fifth Dermatica treatment page in a row, and this one offers a tetracycline.
- No side-effect content for either the topical or the oral.
- Flushing and dilated blood vessels are named as features, and nothing in the pool treats them.
- No fill size and no INCI for the base.
Every active, assessed
- Ivermectin1%
Antiparasitic and anti-inflammatory — reduces Demodex density and the inflammatory response to it
- BENCHMARK
- 1% is the approved concentration
- ASSESSMENT
- The right drug at the right number. Topical ivermectin has the strongest evidence of any topical for papulopustular rosacea, outperforming metronidazole on lesion counts in head-to-head work, and 1% is exactly what the approved product uses. This is the single best-chosen active on any Dermatica page.
- Metronidazole0.75%
Antibacterial and anti-inflammatory — the long-standing first-line topical
- BENCHMARK
- 0.75% and 1% are both approved concentrations
- ASSESSMENT
- The established standard, correctly dosed and published. Decades of trial support for inflammatory lesions and background erythema. Being a topical antimicrobial used for months at a time, it is the kind of drug that benefits from a stated review point, and the page does not give one.
- Azelaic Acid4%–20%
Anti-inflammatory, normalises keratinisation, reduces reactive oxygen species
- BENCHMARK
- 15% is approved for rosacea; 20% is above it
- ASSESSMENT
- A genuinely good rosacea active and the top of this range clears the approved 15%. As on every other Dermatica page the range bottoms out at 4%, which is not a treatment dose, so which end you receive decides whether this is doing the work or supporting it.
- Niacinamide4%
Barrier support, anti-inflammatory, reduces transepidermal water loss
- BENCHMARK
- 2%–5% is the evidenced range
- ASSESSMENT
- The correct supporting choice. Rosacea skin has a measurably impaired barrier and most of what makes treatment intolerable is barrier-driven. A real dose of the right adjunct, and consistent with the page's sensible advice to keep the rest of the routine gentle.
- Doxycycline (oral, optional)NOT STATED — 16-WEEK COURSE AT $59.99
Oral tetracycline — anti-inflammatory at sub-antibiotic dose, antimicrobial above it
- BENCHMARK
- 40 mg modified-release is the only FDA-approved oral for rosacea
- ASSESSMENT
- A legitimate and well-scoped addition — a defined 16-week course rather than an open subscription, which is the structure this register has been asking for. Undermined entirely by the missing dose. Forty milligrams modified-release and a hundred milligrams are equally effective on lesions and completely different propositions on tolerability and resistance, and the page distinguishes them nowhere. Nor does it mention photosensitivity, in a condition where ultraviolet is a trigger.
| ACTIVE | CONC. | BENCHMARK | ASSESSMENT |
|---|---|---|---|
| IvermectinAntiparasitic and anti-inflammatory — reduces Demodex density and the inflammatory response to it | 1% | 1% is the approved concentration | The right drug at the right number. Topical ivermectin has the strongest evidence of any topical for papulopustular rosacea, outperforming metronidazole on lesion counts in head-to-head work, and 1% is exactly what the approved product uses. This is the single best-chosen active on any Dermatica page. |
| MetronidazoleAntibacterial and anti-inflammatory — the long-standing first-line topical | 0.75% | 0.75% and 1% are both approved concentrations | The established standard, correctly dosed and published. Decades of trial support for inflammatory lesions and background erythema. Being a topical antimicrobial used for months at a time, it is the kind of drug that benefits from a stated review point, and the page does not give one. |
| Azelaic AcidAnti-inflammatory, normalises keratinisation, reduces reactive oxygen species | 4%–20% | 15% is approved for rosacea; 20% is above it | A genuinely good rosacea active and the top of this range clears the approved 15%. As on every other Dermatica page the range bottoms out at 4%, which is not a treatment dose, so which end you receive decides whether this is doing the work or supporting it. |
| NiacinamideBarrier support, anti-inflammatory, reduces transepidermal water loss | 4% | 2%–5% is the evidenced range | The correct supporting choice. Rosacea skin has a measurably impaired barrier and most of what makes treatment intolerable is barrier-driven. A real dose of the right adjunct, and consistent with the page's sensible advice to keep the rest of the routine gentle. |
| Doxycycline (oral, optional)Oral tetracycline — anti-inflammatory at sub-antibiotic dose, antimicrobial above it | NOT STATED — 16-WEEK COURSE AT $59.99 | 40 mg modified-release is the only FDA-approved oral for rosacea | A legitimate and well-scoped addition — a defined 16-week course rather than an open subscription, which is the structure this register has been asking for. Undermined entirely by the missing dose. Forty milligrams modified-release and a hundred milligrams are equally effective on lesions and completely different propositions on tolerability and resistance, and the page distinguishes them nowhere. Nor does it mention photosensitivity, in a condition where ultraviolet is a trigger. |
Scoring
- EVIDENCE FOR THE ACTIVEWEIGHT 30%85/100
Three approved topicals at approved strengths, led by the best-evidenced agent in the category, plus a correctly excluded retinoid and a genuinely useful barrier adjunct. Held back because the pool treats papulopustular rosacea and the page describes flushing and dilated vessels, which are a different subtype needing vasoconstrictors or vascular laser — neither in the palette nor mentioned — and because the oral's evidence depends on a dose that is not published.
- FORMULATION INTEGRITYWEIGHT 20%74/100
The best pool design in the range. Every active is first-line for the indication, the concentrations are correct, tretinoin is deliberately absent because retinoids aggravate rosacea, and niacinamide is there for the barrier rather than for the label. The oral is scoped as a defined course rather than a subscription. Marked down for the same unpublished SmartBase INCI as every sibling page, and for the undosed antibiotic.
- DISCLOSUREWEIGHT 15%42/100
The lowest of the four Dermatica topical pages despite publishing every topical concentration, because the failures here are assertions rather than absences. 'Clear rosacea for good' promises a cure for an incurable condition. 'Around 10% of us' is roughly double the pooled prevalence estimate. A 16-week oral antibiotic carries no dose, no resistance note, no photosensitivity warning and no pregnancy warning. Ultraviolet is named as a cause and sunscreen appears nowhere. Credit where due: the trigger-avoidance FAQ is genuinely useful and the eight-week timeline is honest.
- TOLERANCE IN USEWEIGHT 15%NOT ASSESSED
Not assessed, and it matters more here than on any other Dermatica page. Rosacea skin is intolerant by definition, and whether a compounded multi-active in a single base is gentler or harsher than the branded single-agent products it replaces is exactly what a panel would answer.
- TEXTURE & WEARWEIGHT 10%NOT ASSESSED
Not assessed. Requires the product in hand across a full course.
- COST PER APPLICATIONWEIGHT 10%66/100
The strongest value case in the range. Branded ivermectin 1% and the approved sub-antibiotic oral are both expensive, and $29.95 a month with a prescriber included undercuts them substantially. The 16-week oral at $59.99 is reasonable on its face — though a price that low is more consistent with generic antimicrobial-dose doxycycline than with the approved modified-release product, which is another reason to ask. No fill size published, so cost per application is still not computable.
What it is
A compounded prescription cream for rosacea, prescribed after an online consultation, at $29.95 a month following a $4.99 first month. The published pool is four actives — ivermectin 1%, metronidazole 0.75%, azelaic acid 4–20% and niacinamide 4% — blended into the company's SmartBase. Eligible patients can additionally request a 16-week oral doxycycline course at $59.99.
The pool is the best thing this company builds
We have read five Dermatica treatment pages and this is the one where the pharmacology is simply right, without qualification.
- Ivermectin 1% — the concentration of Soolantra, and the topical with the strongest evidence base in rosacea. It reduces Demodex density and, more importantly, the inflammatory cascade the mites provoke.
- Metronidazole 0.75% — the concentration of MetroGel and the agent against which every other rosacea topical has been measured for thirty years.
- Azelaic acid 4–20% — the top of that range clears the 15% approved for rosacea, and azelaic acid works on inflammation and reactive oxygen species rather than by exfoliation.
- Niacinamide 4% — barrier support at a working dose, in a condition defined partly by a barrier that does not hold water.
What is absent is as telling. There is no tretinoin. Retinoids commonly aggravate rosacea, and this is a company whose other four pages are built around tretinoin — it is in the anti-ageing pool, the melasma pool, the skin glow pool, and presumably the unnamed weight-loss formula. Here, where it would do harm, it is gone.
On the skin glow page Dermatica kept hydroquinone and the corticosteroid out of an elective indication. Here it keeps the retinoid out of a condition retinoids irritate. Two deliberate exclusions, both correct, both costing the company an easy upsell. Whatever is wrong with how these pages are written, the person choosing what goes in the bottle knows the field.
And then the headline promises a cure
The largest words on the page are: 'Clear rosacea for good with prescription skincare.'
Rosacea cannot be cleared for good. It is a chronic, relapsing condition with no cure. Treatment suppresses inflammatory lesions and some background erythema; stopping treatment brings them back, which is why maintenance therapy is a standard part of managing it. This is not a contested point in dermatology.
It is not contested by Dermatica either. Two paragraphs below the headline the same page calls rosacea 'a persistent skin condition'. Its FAQ explains that flares are driven by triggers you must keep avoiding. Its own blog, on a different indication, states plainly that there is no cure for melasma — so the company knows how to write that sentence and has written it before.
Everything else we have criticised on these pages has been an absence — no pregnancy warning, no duration limit, no ingredients section. Absences are serious and they are also ambiguous; a missing sentence can be an oversight. This is an assertion, in the largest type on the page, that contradicts the condition, the page's own second paragraph, its own FAQ and its own blog. Delete two words and the headline is fine: 'Clear rosacea with prescription skincare' would be accurate and would sell just as well.
The prevalence figure beside it is inflated too, if less consequentially.
The page states 'around 10% of us have rosacea'. The pooled meta-analytic estimate is about half that. Rates do reach and exceed 10% in specific fair-skinned Northern European populations, so the figure is not invented — but presented flatly as 'us', it roughly doubles the number a reader should have.
Sixteen weeks of an antibiotic, and no milligrams
Partway down the page is an offer: 'Could oral antibiotics be right for you?' A 16-week doxycycline course, $59.99, available to eligible patients after clinical review.
The scoping is good and we should say so. It is a defined course with an end date, not a rolling subscription — which is precisely the structure this register has spent twenty-three reviews asking these companies for. It is gated behind an assessment. Sixteen weeks is a sensible length for oral rosacea therapy.
What is missing is the dose, and for this drug in this condition the dose is not a detail. It is the decision.
Both doses treat rosacea. They are not interchangeable. Sub-antibiotic 40 mg modified-release is the only oral therapy the FDA has approved for rosacea; it matches 100 mg on inflammatory lesion counts while exerting negligible selection pressure for resistance. In head-to-head work the gastrointestinal adverse events sat almost entirely in the 100 mg arm.
This is the sharpest inversion we have found on this site. Dermatica's entire distinguishing virtue — the thing that has kept its scores near seventy despite carrying almost no safety copy — is that it prints the numbers. Ivermectin 1%. Metronidazole 0.75%. Hydroquinone 4%. Fluocinolone 0.01%. Then it adds an oral antibiotic, four months long, and prints no number at all.
Two further omissions follow the same drug. There is no mention of antibiotic resistance anywhere on a page selling sixteen weeks of one. And there is no photosensitivity warning, which for doxycycline is the signature adverse effect — in a condition whose own listed causes include ultraviolet damage.
The trigger advice is good. The biggest trigger is missing.
The FAQ does something the anti-ageing and melasma pages never manage: it gives real, specific self-management advice. Rosacea is trigger-driven, common triggers include certain foods, alcohol, extreme temperatures and stress, and the rest of your routine should stay gentle so the barrier is not further compromised. That is correct and it is genuinely useful.
Sunscreen appears nowhere on the page. Not once.
The page names ultraviolet damage in its own list of what drives rosacea. Sun is among the most consistently reported triggers there is, daily broad-spectrum protection is a cornerstone of management in every guideline, and the optional oral on offer makes patients burn more easily. A page that lists triggers to avoid, names UV as a cause, and omits sunscreen from the avoidance advice has left out the one intervention that is free, universally recommended and directly indicated by its own aetiology paragraph.
One subtype, described as the whole condition
The page describes rosacea as including 'flushing, tingling, inflammation, dilated blood vessels and spots'. That is a fair description of the condition across its presentations.
The pool treats the last two. Ivermectin, metronidazole and azelaic acid act on inflammatory papules and pustules, and reduce the background erythema that comes with them. None of them treats flushing, and none treats established telangiectasia — dilated vessels do not resolve with a cream. Those need a topical vasoconstrictor such as brimonidine or oxymetazoline, or vascular laser. Dermatica offers neither and mentions neither.
This is a milder version of the finding we made against the weight-loss page, and it deserves to be graded as milder. There the product could not touch the mechanism at all. Here it treats the most treatable presentation extremely well and is silent about the ones it cannot reach. A sentence distinguishing the two would cost nothing and would stop the wrong patient buying.
If you are considering it
- Work out which rosacea you have. Bumps and pustules: this is a very good buy. Persistent redness, flushing and visible vessels: this is not the treatment, and no cream is.
- Ask which actives you have been prescribed. Ivermectin and metronidazole are both excellent and they are not the same drug.
- If azelaic acid is in your formula, ask which end of the 4–20% range you are on.
- If you are offered the doxycycline, ask for the dose in milligrams. Forty modified-release is the approved rosacea drug; a hundred is a different proposition on tolerability and resistance.
- If you take the oral, take it with a full glass of water and stay upright afterwards, and treat sun exposure with more caution than usual.
- Wear a daily broad-spectrum sunscreen. The page names UV as a cause and then never mentions it.
- Do the trigger work in the FAQ. For rosacea it is not an adjunct, it is half the treatment.
- Expect control, not cure, and plan for maintenance. The headline is wrong and the second paragraph is right.
Where we stand
At 71 this ties the anti-ageing cream as the highest-scoring Dermatica product, and it gets there by a completely different route. The anti-ageing page scores on disclosure with an ordinary formula. This one has the weakest claims on the site attached to the strongest formula on it — three approved rosacea drugs at approved concentrations, the harmful one deliberately excluded, at a fraction of branded prices.
That gap between the bottle and the copy is now the whole Dermatica story. Somebody here is a competent clinician: they left the retinoid out of rosacea, left the steroid out of skin glow, and dosed ivermectin and metronidazole exactly as the approved products do. Somebody else writes the headlines, and that person has promised a cure for an incurable disease, doubled a prevalence figure, and sold four months of an antibiotic without saying how many milligrams.
Four edits, none of them clinical. Delete 'for good'. Correct the prevalence or attribute it. Put the doxycycline dose on the page with a line about resistance and one about photosensitivity. Add sunscreen to the trigger list where UV already sits. Do that and the best formula this company makes would finally have a page worth the drugs in it.
Who this is for
- Someone with papulopustular rosacea — the bumps and pustules — which is precisely what this pool treats and treats well.
- Someone who wants ivermectin 1% or metronidazole 0.75% without paying branded prices, and knows which they are getting.
- Someone who will ask for the doxycycline dose in milligrams before agreeing to the oral.
- Someone who will do the trigger work the FAQ describes, and add the daily sunscreen it forgets.
- Someone who understands they are buying control rather than the cure the headline offers.
- Your rosacea is mainly persistent redness, flushing and visible vessels. This pool treats inflammatory lesions; that subtype needs a vasoconstrictor or vascular laser, and neither is offered here.
- You are pregnant, breastfeeding or trying to conceive. Nothing on this page warns you, and tetracyclines are contraindicated in pregnancy.
- You would take the oral without knowing the dose.
- You have ocular rosacea as the dominant problem — that needs an ophthalmologist, not a cream.
- You believed the headline. Read the second paragraph of the same page instead.
If you are offered the doxycycline, ask for the milligrams before you agree. Forty and a hundred are different drugs in every way that matters here.
This is an editorial assessment of published information about a prescription product. It is not a diagnosis, not a prescription and not a substitute for your own prescriber. Hydroquinone and tretinoin are drugs. Decisions about them belong with a clinician who has seen your skin.
Sources
- S-01Dermatica — rosacea treatment page The four published actives and concentrations, the 'clear rosacea for good' headline, the 'around 10% of us' prevalence claim, the eight-week timeline, the 16-week $59.99 doxycycline offer without a stated dose, the trigger FAQ, and the absence of sunscreen, side-effect and pregnancy content. Read 27 July 2026.
- S-02Gether et al. — Incidence and prevalence of rosacea: a systematic review and meta-analysis (British Journal of Dermatology, 2018) Pooled prevalence of 5.46% of adults across 32 studies and 41 populations, against the page's 'around 10%'.
- S-03Epidemiology of acne and rosacea: a worldwide global study (JAAD, 2024) Overall rosacea prevalence of 5.1% across 50,552 individuals in 20 countries.
- S-04Long-term inflammatory rosacea management with sub-antibiotic dose doxycycline 40 mg modified-release Sub-antibiotic 40 mg modified-release as the only FDA-approved oral therapy for rosacea, its equivalence to 100 mg on lesion counts, and its negligible selection pressure for resistance.
- S-05Minocycline extended-release compared with doxycycline for rosacea: a randomised head-to-head trial Comparative tolerability data, including gastrointestinal adverse events concentrated in the 100 mg doxycycline arm.
- S-06Dermatica — ingredients index Ivermectin 1% and metronidazole 0.75% in the published palette, and confirmation that tretinoin — present in three other treatment pools — is absent from this one.